Clinical Trials for Liver Cancer

Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor Expressing Autologous T Cells as an Immunotherapy for Children With Solid Tumors (CARE)

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: Children and young adults (1–21 years) with relapsed/refractory GPC3-positive solid tumors (including HCC) receive cyclophosphamide/fludarabine lymphodepletion followed by a single infusion of autologous GPC3-targeted CAR T cells co-expressing IL-15 and IL-21, with an inducible caspase-9 safety switch. The investigational CAR targets the tumor proteoglycan GPC3, with IL-15/IL-21 “armoring” intended to enhance T-cell expansion and persistence.

ClinicalTrials.gov ID: NCT04715191

High Dose-Rate Brachytherapy for the Treatment of Both Primary and Secondary Unresectable Liver Malignancies

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: Adults with unresectable primary or metastatic liver tumors (up to 5 lesions), including those ≥3 cm or adjacent to major vessels/critical structures, adequate hepatic function (not Child-Pugh C), and no active infection receive percutaneous, image-guided high dose-rate brachytherapy using iridium-192. The therapy delivers conformal ablative radiation via temporary intratumoral catheters and is compared to a matched historical cohort for local control and survival outcomes.

ClinicalTrials.gov ID: NCT05053555

A Phase I Clinical Trial Investigating Autologous CAR T Cells Targeting GPC3 in Relapsed or Refractory Hepatocellular Carcinoma

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: Adults with advanced/metastatic GPC3-positive hepatocellular carcinoma after at least two prior lines (including an ICI and a TKI), ECOG 0–1, adequate organ function, and controlled viral hepatitis receive lymphodepleting cyclophosphamide/fludarabine followed by a single infusion of autologous anti-GPC3 CAR T cells (RPCAR01). RPCAR01 targets glypican-3 and includes engineering to reduce TGF-β–mediated immunosuppression; key exclusions include Child-Pugh B/C and CNS disease.

ClinicalTrials.gov ID: NCT06968195

A Phase II Trial of Durvalumab (MEDI4736) and Tremelimumab and Radiation Therapy in Hepatocellular Carcinoma and Biliary Tract Cancer

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: Adults with unresectable or metastatic hepatocellular carcinoma or biliary tract cancer (now BTC only) who are immunotherapy‑naïve receive durvalumab (PD‑L1 inhibitor) plus tremelimumab (CTLA‑4 inhibitor) with hypofractionated radiation to one lesion (8 Gy × 3) during cycle 2, then durvalumab maintenance. Prior therapy requirements vary by histology; patients must have a second measurable non-irradiated lesion and meet liver function and viral hepatitis control criteria.

ClinicalTrials.gov ID: NCT03482102

An International Multicenter Randomized Controlled Trial to Compare Combined Portal and Hepatic Vein Embolization (PVE/HVE) with PVE Alone in Patients with Colorectal Liver Cancer Metastases (CRLM) and a Small Future Liver Remnant (FLR)

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: Adults with colorectal liver metastases and insufficient future liver remnant (<30%, or <40% post-chemotherapy), including select patients with intact primaries and resectable/ablatable extrahepatic disease, are randomized to standard portal vein embolization versus combined portal plus hepatic vein embolization to induce FLR hypertrophy prior to hepatectomy. The trial compares rates and speed of achieving resectable FLR and downstream survival and perioperative outcomes.

ClinicalTrials.gov ID: NCT05428735

An Open-Label, Dose Escalation, Multi-Center Phase I/II Clinical Trial of ECT204 T-Cell Therapy in Adults With Advanced Hepatocellular Carcinoma (HCC) (ARYA-3)

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: Adults with unresectable/metastatic, GPC3-positive HCC after ≥2 prior systemic therapies receive lymphodepleting cyclophosphamide/fludarabine followed by ECT204, an autologous ARTEMIS AbTCR T-cell therapy targeting glypican-3 designed to retain cytotoxicity with reduced cytokine release versus CAR T cells. Phase 2 includes cohorts of ECT204 at the RP2D with or without regorafenib pre-treatment to assess impact on safety and efficacy.

ClinicalTrials.gov ID: NCT04864054

A Phase II Randomized Study of Atezolizumab Plus Multi-Kinase Inhibitor Versus Multi-Kinase Inhibitor Alone in Subjects With Unresectable, Advanced Hepatocellular Carcinoma Who Previously Received Atezolizumab Plus Bevacizumab

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: Adults with unresectable/advanced HCC (ECOG 0–1, Child-Pugh A) who progressed on first-line atezolizumab plus bevacizumab are randomized to cabozantinib or lenvatinib with or without atezolizumab. Atezolizumab is an anti–PD-L1 antibody restoring T-cell activity; cabozantinib and lenvatinib are VEGFR-targeting multi-kinase inhibitors.

ClinicalTrials.gov ID: NCT05168163

Combined Infusion System to Deliver Chemotherapy Regionally to the Liver

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: Adults with colorectal liver metastases or intrahepatic cholangiocarcinoma receive regional hepatic artery infusion of floxuridine (FUDR, antimetabolite) via an implantable Medtronic SynchroMed II pump connected to an Intera tapered catheter, either for unresectable but chemo-responsive liver-dominant disease or post-resection planned HAI. Study focuses on device-combination safety with long-term monitoring; excludes active infection and pregnancy.

ClinicalTrials.gov ID: NCT04684862

Phase 2, Single Arm Study of Tebentafusp and Radioembolization in the Treatment of Metastatic Uveal Melanoma

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: Adults with HLA-A*02:01–positive metastatic uveal melanoma predominantly confined to the liver receive Y-90 transarterial radioembolization followed by weekly tebentafusp. Tebentafusp is a bispecific gp100–HLA-A*02:01–targeted TCR/anti-CD3 ImmTAC that redirects T cells to melanoma cells; key exclusions include large (>8 cm) dominant liver lesions, significant hepatic dysfunction, vascular shunting precluding TARE, and active CNS metastases requiring steroids.

ClinicalTrials.gov ID: NCT06627244

UPCC 04219 Phase 2 Study of Capecitabine-Temozolomide(CapTem) With Yttrium-90 Radioembolization in the Treatment of Patients With Unresectable Metastatic Grade 2/3 Neuroendocrine Tumors

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: Adults with unresectable, liver-dominant, well-differentiated grade 2 or 3 neuroendocrine tumors (ECOG 0–2, measurable liver lesion, adequate organ function, patent portal vein) receive capecitabine-temozolomide (thymidylate synthase inhibition plus DNA alkylation) combined with staged intrahepatic Y-90 radioembolization. Prior systemic therapy is allowed with washout; prior liver-directed embolization or radioembolization is excluded.

ClinicalTrials.gov ID: NCT04339036